Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Efstathios KastritisEvangelos TerposArgiris SymeonidisVasiliki LabropoulouSosana DelimpasiKatia MancusoElena ZamagniEirini KatodritouElena RivoltiMarie-Christine KyrtsonisMaria RoussouDespina FotiouFoteini TheodorakakouIoannis Ntanasis-StathopoulosEvdoxia HatjiharissiNikolaos KanelliasMagdalini MigkouGiorgos CheliotisKyriaki ManousouMaria GavriatopoulouMeletios- Athanasios DimopoulosPublished in: American journal of hematology (2023)